Background: Tuberculosis immune reconstitution inflammatory syndrome is an uncommon condition caused by excessive immune response against Mycobacterium tuberculosis. We report on a case which may have been precipitated by coronavirus disease messenger ribonucleic acid vaccine booster.
Case Presentation: A 47-year old Indian man developed reactivation tuberculosis in the cervical lymph nodes in the setting of immune suppression caused by tumor necrosis factor inhibitor adalimumab. The symptoms improved with starting antituberculous therapy, but 5 days after receiving a coronavirus disease booster messenger ribonucleic acid vaccine, he had recurrence of severe constitutional symptoms. After a detailed evaluation, he was diagnosed with immune reconstitution inflammatory syndrome and was successfully treated with high-dose steroid therapy, which was weaned off over several weeks.
Conclusion: Immune reconstitution inflammatory syndrome should be considered as a differential in patients who develop paradoxical worsening of symptoms with antitubercular therapy in the setting of immune reconstitution. Hyperactive immune response after infection or messenger ribonucleic acid vaccine booster may have contributed to the development of immune reconstitution inflammatory syndrome syndrome in this patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877773 | PMC |
| http://dx.doi.org/10.1186/s13256-025-05081-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
T-cell Recovery After Autologous Hematopoietic Stem Cell Transplantation in Autoimmune Diseases.
Adv Exp Med Biol
March 2025
Center for Cell-Based Therapy, Regional Blood Center, Ribeirão Preto, SP, Brazil.
Over the last three decades, autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a significant therapeutic strategy for patients with various refractory autoimmune diseases. Globally, more than 3000 AHSCT procedures have been performed for severe autoimmune diseases. The rationale behind this treatment is abrogation of autoreactivity; renovation of the immune system from the infused hematopoietic stem cells and establishment of a balanced, long-lasting, and self-tolerant immune system.
View Article and Find Full Text PDFLyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Hum Vaccin Immunother
December 2025
Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.
The World Health Organization (WHO) has recently declared another global health emergency due to the rapidly spreading monkeypox (Mpox) outbreak in numerous African countries. To address the unmet need to contain the outbreak using the existing vaccines, this study developed a lyophilization process for an effective, scalable and affordable Mpox mRNA-LNP vaccine candidate to address the global health crisis. A comprehensive evaluation and optimization of the vaccine formulation (the type/concentration of cryoprotectants, the type/concentration of buffer system, as well as the mRNA concentration and reconstitution solvent) and the freeze-drying process parameters (freezing method, temperature, cooling rate and primary/secondary drying conditions) were conducted.
View Article and Find Full Text PDFImpaired immune reconstitution in HIV infection: the role of CD4 T-cell-associated NKG2D ligands, CD4 T-cell subsets imbalance, and immune function deficiency.
Front Immunol
March 2025
Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Objective: The role of natural killer (NK) cells, which mediate innate immunity, in the immune reconstitution of people living with HIV (PLWH) remains unclear. Our previous research indicated that early activation of CD56CD16 NK cells plays an important role in the recovery of CD4 T cells in immunological non-responders (INRs) after ART. This study mainly focuses on the profiles of cell receptors and their relative ligands for NK cells and CD4 T cells exhibited on INRs and immunological responders (IRs) in order to analyze the impact of differential immune status on immune reconstitution in PLWH receiving ART.
View Article and Find Full Text PDFSuccessful hematopoietic cell transplant requires immunosuppression to prevent graft-versus-host disease (GVHD), a lethal, T-cell-mediated post-transplant complication. The phase 3 BMT CTN 1703 trial demonstrated superior GVHD-free/relapse-free survival for post-transplant cyclophosphamide (PT-Cy)-based GVHD prophylaxis versus tacrolimus/methotrexate (Tac/MTX), but did not improve overall survival. To compare T-cell biology between GVHD prophylaxis regimens, 324 patients were co-enrolled onto BMT CTN 1801 ( NCT03959241 ).
View Article and Find Full Text PDFHematopoietic stem cell transplant, chimeric antigen receptor T-cells, and other cellular therapies as stepping stones toward long-term improvement in severe scleroderma and other autoimmune diseases.
Semin Arthritis Rheum
February 2025
James B. Wyngaarden Professor Emeritus of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:
Preclinical models of inherited and induced autoimmune diseases (AIDs) have shown that hematopoietic stem cell transplantation (HSCT) following high-dose immunosuppressive conditioning could reverse organ damage and alter the course of AIDs. The rationale for both autologous and allogeneic HSCT has been based upon a reset of the immune system. Clinical application of HSCT was initially focused on severe systemic sclerosis (SSc) and three randomized trials comparing autologous HSCT with standard cyclophosphamide (CY) demonstrated significant improvement in SSc measured 12-54 months after transplant.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!